Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/49007Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | BRAEYE, Toon | - |
| dc.contributor.author | De Pauw, Robby | - |
| dc.contributor.author | Geebelen, Laurence | - |
| dc.contributor.author | ABRAMS, Steven | - |
| dc.contributor.author | Desombere, Isabelle | - |
| dc.contributor.author | HENS, Niel | - |
| dc.contributor.author | Hammami, Naïma | - |
| dc.contributor.author | Roelants , Mathieu | - |
| dc.contributor.author | Muylaert, An | - |
| dc.contributor.author | HERZOG, Sereina | - |
| dc.date.accessioned | 2026-05-08T07:28:51Z | - |
| dc.date.available | 2026-05-08T07:28:51Z | - |
| dc.date.issued | 2026 | - |
| dc.date.submitted | 2026-04-24T12:33:33Z | - |
| dc.identifier.citation | Archives of public health, 84 (1) (Art N° 76) | - |
| dc.identifier.uri | http://hdl.handle.net/1942/49007 | - |
| dc.description.abstract | BackgroundBelgium experienced two SARS-CoV-2 epidemic waves in 2020, in spring and autumn. Due to limited testing capacity, restrictive case definitions, asymptomatic infections, and incomplete testing compliance, case counts represent only a lower bound of SARS-CoV-2 infection incidence. We estimated this incidence from February 2020 to January 2021 by jointly modelling seroprevalence and surveillance data.MethodsWe developed a hierarchical Bayesian model that jointly fits seroprevalence, hospitalization, and mortality data to a shared latent incidence curve, represented by a spline. The model accounts for time-varying serological test sensitivity (reflecting seroconversion and seroreversion) using informative priors, and simultaneously estimates test specificity, infection-to-event distributions, and time-varying infection hospitalization rates (IHR) and infection fatality rates (IFR). Seroprevalence data comprised 37,235 samples from two repeated cross-sectional studies: residual laboratory samples tested with the EuroImmun IgG ELISA and blood donor samples tested with the Wantai Ab ELISA. Hospitalization and mortality counts were obtained from national COVID-19 surveillance.ResultsBy early 2021, an estimated 19.0% (95% Credible Interval (CrI) 17.4-20.7), 13.6% (CrI 11.5-15.8) and 10.8% (CrI 8.7-13.2) of the Belgian 18-49, 50-64 and 65-74 year-olds had been infected with SARS-CoV-2. The first wave mostly affected the younger age group, with a peak weekly incidence of 2.0% (CrI 1.7-2.3) late March 2020. The second wave peaked late October 2020 with weekly incidences of 1.6% (CrI 1.2-2.1) among 65-74 year-olds and 2.8% (CrI 2.4-3.3) among 18-49 year-olds. IHR and IFR were considerably higher in older age groups and declined over time. Among 65-74 year-olds IHR declined from 9.9% (CrI 7.3-14.2) to 5.0% (CrI 3.5-7.1) and IFR from 2.8% (CrI 2.0-4.0) to 1.2% (CrI 0.9-1.7).ConclusionAn estimated 16.3% (CrI 15.1-17.4) of the Belgian adult population had been infected with SARS-CoV-2 by early 2021. Joint modelling of seroprevalence and surveillance data provides a framework for estimating infection burden. | - |
| dc.description.sponsorship | Funding The BDS seroprevalence study was supported by the Belgian Federal Government through Sciensano (grants COVID-19_SC004, COVID-19_SC005, and COVID-19_SC080). The RLS seroprevalence study received funding from the European Union’s Horizon 2020 research and innovation program - project EpiPose (No 101003688), the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement 682540 TransMID), the Flemish Research Fund (FWO 1150017 N) and from The Antwerp University Fund, which is a community of donors who contribute to research and education with their personal commitment through a donation, gift, bequest or through academic chairs. The funders had no role in study design, data collection, data analysis, data interpretation, writing or submitting of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. Acknowledgements We acknowledge Caroline Rodeghiero, Fabienne Jurion, Christophe Van den Poel, Sara Vande Kerckhove, Elfriede Heerwegh, Elien De Vits, Jessie Claessens, Veerle Van Melle and Martine Clinet for their excellent work in managing and analysing the thousands of plasma samples. We also thank Dominique Goossens for coordinating the study at the side of the red cross (BDS study). We acknowledge the Belgian laboratories that voluntarily collected sera and data for this study: Algemeen Medisch Laboratorium (AML, Antwerpen), Laboratoire Luc OLIVIER (Fernelmont), Declerck Klinisch Laboratorium (Ardooie), Klinisch Labo RIGO (Genk), Labo Anacura/Nuytinck (Evergem), Labo Somedi (Heist-op-den-Berg), Labo LBS (Brussels), Laboratoire Bauduin (Enghien), Medisch labo Bruyland (Kortrijk), Synlab (Luik). | - |
| dc.language.iso | en | - |
| dc.publisher | BMC | - |
| dc.rights | The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. | - |
| dc.subject.other | Seroprevalence | - |
| dc.subject.other | Incidence | - |
| dc.subject.other | SARS-CoV-2 | - |
| dc.subject.other | COVID-19 | - |
| dc.subject.other | Statistical modelling | - |
| dc.subject.other | Surveillance data | - |
| dc.subject.other | Seroconversion | - |
| dc.subject.other | Seroreversion | - |
| dc.subject.other | Bayesian hierarchical model | - |
| dc.title | Estimating the incidence of SARS-CoV-2 infections by jointly modelling seroprevalence, hospitalization and mortality data, February 2020-January 2021, Belgium | - |
| dc.type | Journal Contribution | - |
| dc.identifier.issue | 1 | - |
| dc.identifier.volume | 84 | - |
| local.format.pages | 13 | - |
| local.bibliographicCitation.jcat | A1 | - |
| dc.description.notes | Braeye, T (corresponding author), Dept Epidemiol & Publ Hlth, Sciensano, Brussels, Belgium.; Braeye, T (corresponding author), UHasselt, Interuniv Inst Biostat & Stat Bioinformat BioSta 1, Data Sci Inst DSI, Hasselt, Belgium. | - |
| dc.description.notes | toon.braeye@sciensano.be | - |
| local.publisher.place | CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND | - |
| local.type.refereed | Refereed | - |
| local.type.specified | Article | - |
| local.bibliographicCitation.artnr | 76 | - |
| local.type.programme | H2020 | - |
| local.relation.h2020 | 682540 TransMID | - |
| dc.identifier.doi | 10.1186/s13690-026-01860-z | - |
| dc.identifier.pmid | 41787546 | - |
| dc.identifier.isi | 001739092400001 | - |
| local.provider.type | wosris | - |
| local.description.affiliation | [Braeye, Toon; De Pauw, Robby; Geebelen, Laurence] Dept Epidemiol & Publ Hlth, Sciensano, Brussels, Belgium; [Braeye, Toon; Abrams, Steven; Hens, Niel] UHasselt, Interuniv Inst Biostat & Stat Bioinformat BioSta 1, Data Sci Inst DSI, Hasselt, Belgium; [De Pauw, Robby] Ghent Univ, Fac Hlth Sci & Med, Ghent, Belgium; [Abrams, Steven] Univ Antwerp, Global Hlth Inst, Family Med & Populat Hlth FAMPOP, Antwerp, Belgium; [Desombere, Isabelle] Sciensano, Dept Infect Dis Humans, Lab Immune Response, Brussels, Belgium; [Hens, Niel] Univ Antwerp, Vaccine & Infect Dis Inst Vaxinfectio, Ctr Hlth Econ Res & Modelling Infect Dis CHERMID, Antwerp, Belgium; [Hammami, Naïma; Roelants, Mathieu] Flemish Community, Dept Care, Team Infect Prevent & Vaccinat, Brussels, Belgium; [Muylaert, An] Labo Nuytinck, Evergem, Belgium; [Muylaert, An] Red Cross Flanders, Dienst Bloed, Mechelen, Belgium; [Herzog, Sereina A.] Med Univ Graz, Inst Med Informat Stat & Documentat, Graz, Austria | - |
| local.uhasselt.international | yes | - |
| item.contributor | BRAEYE, Toon | - |
| item.contributor | De Pauw, Robby | - |
| item.contributor | Geebelen, Laurence | - |
| item.contributor | ABRAMS, Steven | - |
| item.contributor | Desombere, Isabelle | - |
| item.contributor | HENS, Niel | - |
| item.contributor | Hammami, Naïma | - |
| item.contributor | Roelants , Mathieu | - |
| item.contributor | Muylaert, An | - |
| item.contributor | HERZOG, Sereina | - |
| item.accessRights | Open Access | - |
| item.fulltext | With Fulltext | - |
| item.fullcitation | BRAEYE, Toon; De Pauw, Robby; Geebelen, Laurence; ABRAMS, Steven; Desombere, Isabelle; HENS, Niel; Hammami, Naïma; Roelants , Mathieu; Muylaert, An & HERZOG, Sereina (2026) Estimating the incidence of SARS-CoV-2 infections by jointly modelling seroprevalence, hospitalization and mortality data, February 2020-January 2021, Belgium. In: Archives of public health, 84 (1) (Art N° 76). | - |
| crisitem.journal.issn | 0778-7367 | - |
| crisitem.journal.eissn | 2049-3258 | - |
| Appears in Collections: | Research publications | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| s13690-026-01860-z.pdf | Published version | 2.28 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.